Core Points - NRx Pharmaceuticals, Inc. will present at NobleCon21 on December 3rd, 2025, focusing on its expanded initiatives in investigational drugs and therapies for mental health conditions [1][2] - The company has begun generating clinical revenue and has made significant advancements in drug development since its last appearance at NobleCon in 2024 [2] Company Overview - NRx Pharmaceuticals is a clinical-stage biopharmaceutical company specializing in Neuroplastic Therapies for central nervous system disorders, including suicidal depression, PTSD, anxiety, and Autism [5] - The company is developing NRX-100 (preservative-free intravenous ketamine) and NRX-101 (oral D-cycloserine/lurasidone), with NRX-100 receiving Fast Track Designation for treating suicidal ideation in depression and NRX-101 receiving Breakthrough Therapy Designation for suicidal bipolar depression [5] - NRx has filed an Abbreviated New Drug Application for its ketamine formulation, anticipating a launch in July 2026 [5] HOPE Therapeutics Overview - HOPE Therapeutics, a subsidiary of NRx, is establishing a network of interventional psychiatry clinics offering various therapies, including ketamine and transcranial magnetic stimulation [6] - The network is the first in Florida to provide the AMPA One Day (ONE-D) treatment, which combines TMS, physician-prescribed D-cycloserine, and lisdexamfetamine for treatment-resistant depression [6] Conference Details - Interested investors can attend the presentation at a discounted rate using a specific discount code [3] - A high-definition video webcast of the presentation will be available on the company's website and other platforms for 90 days following the event [4]

Core Insights - HOPE Therapeutics, Inc. has acquired a strategic interest in Cohen and Associates, LLC, integrating it into the HOPE Network, with Dr. Rebecca Cohen appointed as Medical Director overseeing care standards in Florida [1][9] Company Overview - HOPE Therapeutics is a subsidiary of NRx Pharmaceuticals, focusing on building a network of interventional psychiatry clinics offering treatments such as ketamine and Transcranial Magnetic Stimulation (TMS) for patients with suicidal depression and related disorders [7] - NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics for central nervous system disorders, including suicidal depression and PTSD, with products like NRX-100 and NRX-101 [6] Leadership and Expertise - Dr. Rebecca Cohen is a recognized expert in TMS and has a strong academic background, having founded her practice in 2014 as one of the first dedicated interventional psychiatry practices in the U.S. [3][9] - The leadership team at HOPE, including Dr. Cohen and Stephen Durand, RN, aims to advance interventional psychiatry and expand treatment options for patients [4][5] Strategic Goals - The acquisition of Cohen, LLC is expected to enhance HOPE Therapeutics' revenue and EBITDA, with immediate expansion plans in Western Florida and Palm Beach [9]